DK3049059T3 - Intranasal dhe formulering til behandlingen af hovedpine - Google Patents

Intranasal dhe formulering til behandlingen af hovedpine Download PDF

Info

Publication number
DK3049059T3
DK3049059T3 DK14830861.2T DK14830861T DK3049059T3 DK 3049059 T3 DK3049059 T3 DK 3049059T3 DK 14830861 T DK14830861 T DK 14830861T DK 3049059 T3 DK3049059 T3 DK 3049059T3
Authority
DK
Denmark
Prior art keywords
headache
treatment
dhe formulation
intranasal
intranasal dhe
Prior art date
Application number
DK14830861.2T
Other languages
English (en)
Inventor
Shunji Haruta
Nikhilesh N Singh
John Kollins
Salvador Rico
Original Assignee
Satsuma Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satsuma Pharmaceuticals Inc filed Critical Satsuma Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3049059T3 publication Critical patent/DK3049059T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14830861.2T 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine DK3049059T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881947P 2013-09-24 2013-09-24
PCT/IB2014/002706 WO2015044782A2 (en) 2013-09-24 2014-09-24 Intranasal dhe for the treatment of headache

Publications (1)

Publication Number Publication Date
DK3049059T3 true DK3049059T3 (da) 2022-01-31

Family

ID=52424045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14830861.2T DK3049059T3 (da) 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine

Country Status (6)

Country Link
US (5) US20160228433A1 (da)
EP (2) EP4008307A1 (da)
JP (2) JP2016531850A (da)
DK (1) DK3049059T3 (da)
ES (1) ES2904570T3 (da)
WO (1) WO2015044782A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8757146B2 (en) 2008-02-07 2014-06-24 University Of Washington Through Its Center For Commercialization Circumferential aerosol device
JP6339371B2 (ja) 2011-03-03 2018-06-06 インペル ニューロファーマ インコーポレイテッド 経鼻薬物送達デバイス
CN103619485B (zh) 2011-05-09 2017-08-08 英倍尔药业股份有限公司 用于鼻腔药物递送的喷嘴
EP2991713B1 (en) 2013-04-28 2019-06-19 Impel Neuropharma Inc. Medical unit dose container
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
MX2018002895A (es) 2015-09-10 2018-07-06 Impel Neuropharma Inc Dispositivo de administracion nasal en linea.
EP3493789A2 (en) 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
BR112019027508A2 (pt) * 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
EP3713626A4 (en) 2017-11-21 2021-08-18 Impel Neuropharma Inc. INTRA-NASAL DEVICE WITH INPUT INTERFACE
BR112020013750A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
JP7317020B2 (ja) * 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
CN120284965A (zh) * 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
WO2020142206A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
CN114025816A (zh) 2019-05-17 2022-02-08 英倍尔药业股份有限公司 一次性鼻腔给送装置
AU2024282997A1 (en) * 2023-05-31 2026-01-22 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
ATE290864T1 (de) * 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
JP3197221B2 (ja) * 1996-02-27 2001-08-13 帝人株式会社 吸収性が改善された粉末状経鼻投与組成物
SE9803770D0 (sv) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
JP4691298B2 (ja) * 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法
JP2004531333A (ja) * 2001-06-20 2004-10-14 ネクター セラピューティクス 粉末エアロゾル化装置及び方法
KR20030027108A (ko) * 2001-07-05 2003-04-03 트렌스레셔널 리서치 가부시키가이샤 인슐린의 경비 투여용 조성물
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
JP4212019B2 (ja) * 2002-01-09 2009-01-21 Translational Research 株式会社 薬物の経鼻投与用組成物
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
JP2007505136A (ja) 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CA2617909C (en) * 2005-08-05 2014-02-04 3M Innovative Properties Company Compositions exhibiting improved flowability
US8106100B2 (en) * 2005-12-06 2012-01-31 Asahi Kasei Chemicals Corporation Process for producing tablet by high-speed direct compression
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP2009076785A (ja) * 2007-09-21 2009-04-09 Panasonic Corp 半導体装置の製造方法
US20110082150A1 (en) 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2010151804A1 (en) 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
IN2012DN04858A (da) 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
CN103126996A (zh) * 2010-04-15 2013-06-05 株式会社新日本科学 用于鼻内递送的方法和组合物
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
CA2825541C (en) 2011-01-31 2020-06-02 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
JP6339371B2 (ja) 2011-03-03 2018-06-06 インペル ニューロファーマ インコーポレイテッド 経鼻薬物送達デバイス
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
US20140179705A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
EP3493789A2 (en) 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
JP7523879B2 (ja) 2016-10-31 2024-07-29 エスエス製薬株式会社 医薬組成物
BR112019027508A2 (pt) 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
JP7317020B2 (ja) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法

Also Published As

Publication number Publication date
WO2015044782A3 (en) 2015-06-11
JP6902583B2 (ja) 2021-07-14
EP4008307A1 (en) 2022-06-08
US20200179379A1 (en) 2020-06-11
US20230000860A1 (en) 2023-01-05
JP2020007342A (ja) 2020-01-16
EP3049059A2 (en) 2016-08-03
US12594273B2 (en) 2026-04-07
EP3049059B1 (en) 2021-11-03
JP2016531850A (ja) 2016-10-13
WO2015044782A2 (en) 2015-04-02
ES2904570T3 (es) 2022-04-05
US20240108619A1 (en) 2024-04-04
US20160228433A1 (en) 2016-08-11
US20190275036A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
DK3049059T3 (da) Intranasal dhe formulering til behandlingen af hovedpine
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3603794T3 (da) Fremgangsmåde til overflader med gelmønster
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK2994238T3 (da) Belægningsanordning til termisk belægning
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
HRP20180460T1 (hr) Inhibitori syk
IL243577A0 (en) Formulation of syk inhibitors
HUE036383T2 (hu) Bevonási eljárás
HUE042443T2 (hu) GPR6 tetrahidropiridopirazin-modulátorai
PL3427584T3 (pl) Sposób zwalczania rdzy
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK2992104T3 (da) Fremgangsmåde til ekspression
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
PT2953948T (pt) Antagonistas de integrina fluorada
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
EP2945942A4 (en) Voriconazole IMMUNOASSAY
HRP20181122T1 (hr) Postupak za pripremu jopamidola